Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections [1][4] - The company will present at the 10th Annual Innate Killer Summit, highlighting its Decoy platform designed to activate multiple arms of the immune system, including NK cells, to combat cancer [2][4] Company Overview - Indaptus Therapeutics has developed a novel approach based on the hypothesis that efficient activation of both innate and adaptive immune cells is necessary for effective anti-tumor and anti-viral responses [4] - The Decoy platform utilizes attenuated and killed non-pathogenic Gram-negative bacteria to produce a multi-targeted immune response, aiming to reduce intravenous toxicity while maintaining immune activation capabilities [4] Scientific Presentation - Dr. Michael Newman will present on March 4, 2025, discussing the use of attenuated and killed Gram-negative bacteria to induce NK-mediated anti-tumor immunity [2] - The presentation will emphasize the alignment of Indaptus' approach with next-generation immune-based therapies [2] Pre-Clinical Findings - Decoy product candidates have shown single-agent activity against various cancers, including metastatic pancreatic and colorectal carcinomas, and have demonstrated combination-mediated eradication in pre-clinical models [4] - The product candidates have also exhibited significant activity against chronic hepatitis B virus and chronic human immunodeficiency virus infections in pre-clinical studies [4]
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit